Quote · God Mode Podcast
SpaceX's $2T IPO, Karpathy Joins Anthropic & the SaaSpocalypse — ft. Dr Dan | EP14
Where this was said
GLP-1 Peptides Explained: From Ozempic to Retatrutide
At 52:45 · chapter starts 51:50
Retatrutide Phase 3 trials showed 28.3% body weight loss on 12mg over 80 weeks, significantly outperforming earlier GLP-1 drugs.
Ozempic triggered a revolution by cutting injections from twice daily to once weekly. Retatrutide adds a third receptor key — GLP-1, GIP, and glucagon — delivering 28.3% body weight loss in Phase 3 trials. Think of each generation as a Pokemon evolution, and we're not close to the final form.
Natural GLP-1 has a half-life of only 30 minutes in the blood; drug engineers have extended this to enable weekly injections with sustained effect.
Ozempic unlocked mass market adoption by reducing injections from twice daily (liraglutide) to once weekly while doubling the therapeutic effect.
Taking a drug from early research to market approval costs an average of $2.3 billion and takes a median of 15 years.
Brand-name Ozempic costs around $400 per month in the US, while equivalent peptides sourced from China cost $10–20, a 20-40x price gap.
Developing a drug costs $2.3 billion over 15 years. You get 8 years to recoup it before generics hit. Meanwhile, US compounding pharmacies exploit a loophole to sell unbranded Ozempic for $50 instead of $1,500. It's the AI subscription pricing model applied to pharmaceuticals.
